跳至主要内容
临床试验/NCT07396194
NCT07396194尚未招募不适用

Evaluation of the Relation Between Serum Interleukins 17, 38, 41, and HLA-B27 Gene Expression in Ankylosing Spondylitis Patients

Sohag University0 个研究点目标入组 84 人开始时间: 2026年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
84
主要终点
collection of blood samples from paticipants

研究概览

简要总结

The goal of this observational study is to measure the serum level of cytokines IL-17, IL-38,IL-41, and gene expression of HLA-B27 gene in ankylosing spondylitis patients and healthy control group.

The main question it aims to answer is:

Does the disease activity, severity, serum level of cytokines (IL-17, IL-38, and IL-41) are affected by the HLA-b27 gene positivity?

Researchers will compare the serum level of cytokines IL-17, IL-38,IL-41, and gene expression of HLA-B27 gene in ankylosing spondylitis patients and healthy control group to see if there significant differences in serum levels of interleukins 17, 38, 41 in AS patients and healthy control group.

.

详细描述

Ankylosing spondylitis (AS) that is known as radiographic SpA (r-axSpA), is a type of axial spondyloarthritis, characterized by the dual pathology of inflammatory bone erosion and aberrant new bone formation. It is characterized by chronic inflammation affecting the sacroiliac joints and spine, leading over time to structural changes such as syndesmophyte formation and spinal ankylosis, with consequent impairment in function and quality of life. As an autoimmune disease, it may also affect several organs, including the eyes, intestines, heart, and lungs .

The global prevalence of AS ranges from 0.3 % to 1.4 %, with a strong predilection for young adult males, in whom mobility and quality of life are often severely impaired. Reports indicate that the global incidence of AS ranges from 0.07 to 0.32%, with a male prevalence 2-3 times higher than that of females .

The etiopathogenesis of spondylo-arthritis is still not fully understood but it has been described as involving several mechanisms of action that synergistically initiate and maintain a pro-inflammatory state, leading to disease onset . Numerous disciplines, including genetics, environment, gut microbiota, and hormones, have previously been studied in relation to the etiology of AS .

Genetic predisposition - particularly carriage of the Human Leukocyte Antigen B27 (HLA-B27) allele - is closely linked to AS susceptibility and underlies several immunopathogenic hallmarks of the disease. There is a growing interest in HLA-B27-based effects, particularly in HLA-B27(+) patients who have AS, although the diagnostic and prognostic functions of HLA-B27 in AS are still being contested. Patients with HLA-B27 positivity have a considerably younger age at onset, a greater number of cases of uveitis, and a higher frequency of involvement of peripheral joints compared to patients with HLA-B27 negative.

The development of inflammatory arthritis is dependent upon the presence of an unbalanced cytokine network. Several interleukins and chemokines, particularly those with pro-inflammatory effects such as tumor necrosis factor (TNF)-α, interleukin (IL)-17A and C-X-C motif chemokine ligand 10 (CXCL10), are involved in mediating inflammation and consequent tissue damage.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
16 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients who are diagnosed clinically as ankylosing spondylitis (both active or stable), of either sex , who met the Assessment of Spondyloarthritis International Society (ASAS) criteria for axial spondyloarthritis.

排除标准

  • Patients with any autoimmune disorder, chronic illnesses as diabetes mellitus, acute and chronic infectious diseases, malignancy.

研究组 & 干预措施

Cases

Patients with Ankylosing spondylitis

Healthy Controls

Participants Without Ankylosing spondylitis

结局指标

主要结局

collection of blood samples from paticipants

时间窗: from March 2026 to August 2026

measurement of serum level of Interleukin 17 in participants

时间窗: From September 2026 to October 2026

Measurement of serum level of Interleukin 38 in participants

时间窗: from September 2026 to October 2026

measurement of serum level of Interleukin 41 in participants

时间窗: from September 2026 to October 2026

measurement of gene expression of HLA- B27 gene in participants

时间窗: from October 2026 to December 2026

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alaa Ezat Ahmed

Assisstant lecturer

Sohag University

相似试验